Results
|
101.
|
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. MedStar authors:
Year: 2019
Citation: - Lancet Oncology. 20(1):88-99, 2019 01.
Institution: - MedStar Franklin Square Medical Center
Medline publication type:
All authors: - Bandos H, Brufsky AM, Chia SK, Dakhil SR, Fehrenbacher L, Geyer CE Jr, Graham ML, Jeong JH, Lembersky BC, Mamounas EP, McCarron EC, Paik S, Rastogi P, Seay TE, Soori GS, Swain SM, Wade JL 3rd, Walshe JM, Wickerham DL, Wolmark N
|
|
102.
|
The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study. MedStar authors:
Year: 2018
Citation: - Breast Cancer Research & Treatment. 167(3):741-749, 2018 02.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Beebe-Dimmer JL, Bock CH, Cote ML, Desai P, Dyson G, Hou L, Howard BV, Jay AM, Prentice R, Purrington K, Simon MS
|
|
103.
|
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. MedStar authors:
Year: 2015
Citation: - New England Journal of Medicine. 372(8):724-34, 2015 Feb 19.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, CLEOPATRA Study Group, Cortes J, Ferrero JM, Heeson S, Kim SB, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM
|
|
104.
|
|
|
105.
|
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. MedStar authors:
Year: 2015
Citation: - Journal of Clinical Oncology. 33(12):1340-7, 2015 Apr 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Blackmon NL, Costantino JP, Fehrenbacher L, Finnigan M, Gavin PG, Geyer CE Jr, Jeong JH, Kim SR, Mamounas EP, Paik S, Pogue-Geile KL, Rastogi P, Song N, Swain SM, Wickerham DL, Wolmark N
|
|
106.
|
A case of checkpoint inhibitor-induced celiac disease. MedStar authors:
Year: 2019
Citation: - Journal for Immunotherapy of Cancer. 7(1):203, 2019 08 05.
Institution: - MedStar Washington Hospital Center
Department: - Medicine/Internal Medicine
Medline publication type:
All authors: - Alsaadi D, Atkins MB, Charabaty A, Shah NJ
|
|
107.
|
|
|
108.
|
|
|
109.
|
Vemurafenib-induced DRESS. MedStar authors:
- Jang, Sekwon
- Nasabzadeh, Teresa
- Pichard, Dominique C
- Wenk, Kurt S
Year: 2013
Citation: - JAMA Dermatology. 149(10):1242-3, 2013 Oct.
Institution:
- MedStar Washington Hospital Center
- Washington Cancer Institute
Medline publication type:
- Case Reports
- Journal Article
All authors: - Jang S, Nasabzadeh T, Pichard DC, Venna SS, Wenk KS
|
|
110.
|
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. MedStar authors:
Year: 2013
Citation: - Journal of Clinical Oncology. 31(26):3197-204, 2013 Sep 10.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
All authors: - Atkins JN, Azar CA, Biggs DD, Brufsky AM, Costantino JP, Donnellan PP, Fehrenbacher L, Geyer CE Jr, Levine EA, Mamounas EP, Northfelt DW, Paik S, Polikoff JA, Provencher L, Rastogi P, Robidoux A, Swain SM, Tang G, Wolmark N, Zapas JL
|
|
111.
|
|
|
112.
|
|
|
113.
|
Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer. MedStar authors:
Year: 2014
Citation: - Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer. 9(1):121-5, 2014 Jan.
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase I
- Clinical Trial, Phase II
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Adams JW, Berger MS, Chiappori A, Edelman MJ, Haura EB, Malik S, Northfelt DW, Rosen P, Van Echo DA, Williams C
|
|
114.
|
|
|
115.
|
Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials. MedStar authors:
- Blackburn, Matthew J
- Lynce, Filipa
Year: 2018
Citation: - Breast Cancer Research & Treatment. 168(1):35-41, 2018 Feb.
Institution:
- MedStar Washington Hospital Center
- Washington Cancer Institute
Medline publication type:
All authors: - Blackburn MJ, Cai L, Harris P, Isaacs C, Lynce F, Pohlmann PR, Rubinstein L, Wang H
|
|
116.
|
Avastin withdrawal symptoms. MedStar authors:
- Lynce, Filipa
- Swain, Sandra M
Citation: - Expert Opinion on Pharmacotherapy. 13(3):293-8, 2012 Feb.
Institution: - Washington Cancer Institute
Medline publication type:
- Editorial
- Research Support, Non-U.S. Gov't
|
|
117.
|
Perioperative Management of Antiplatelet Therapy in Patients With History of Coronary Artery Disease Undergoing Surgery for Esophageal Cancer: A Single-center Experience. MedStar authors:
Year: 2019
Citation: - In Vivo. 33(2):621-626, 2019 Mar-Apr.
Institution: - MedStar Washington Hospital Centerumar
Department: - Medicine/General Internal Medicine
Medline publication type:
All authors: - Bakopoulos A, Domi V, Jonnalagadda AK, Kapelouzou A, Kokkinidis DG, Liakakos T, Mpaili E, Schizas D, Theochari CA, Theochari NA
|
|
118.
|
Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. MedStar authors:
- Sugarbaker, Paul H
- Yan, Tristan D
Year: 2012
Citation: - Journal of Clinical Oncology. 30(20):2449-56, 2012 Jul 10.
Institution:
- MedStar Washington Hospital Center
- Washington Cancer Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Research Support, Non-U.S. Gov't
All authors: - Baratti D, Barrios P, Ceelen WP, Chua TC, de Hingh IH, Deraco M, Elias D, Gilly FN, Glehen O, Gomez Portilla A, Gonzalez-Moreno S, Levine EA, Liauw W, Moran BJ, Morris DL, Pelz JO, Piso P, Sardi A, Sugarbaker PH, Van Der Speeten K, Yan TD
|
|
119.
|
Pharmacokinetics of doxorubicin in pregnant women. MedStar authors:
- Miodovnik, Menachem
- Umans, Jason G
Year: 2014
Citation: - Cancer Chemotherapy & Pharmacology. 73(4):789-97, 2014 Apr.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
All authors: - Akbarzadeh A, Berg SL, Easterling TR, Eyal S, Feldman EM, Hays K, Hebert MF, Kaplan HG, Miodovnik M, Puhl K, Ryu RJ, Scorsone KA, Umans JG
|
|
120.
|
|
|
121.
|
|
|
122.
|
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study. [] MedStar authors:
Year: 2015
Citation: - Breast Cancer Research & Treatment. 149(1):163-9, 2015 Jan.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase II
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Bhatt K, Bury MJ, Fehrenbacher L, Flynn PJ, Geyer CE Jr, Goel R, Jacobs SA, Johannes H, Julian TB, Mamounas EP, Provencher L, Rastogi P, Robidoux A, Stella PJ, Swain SM, Tan AR, Thirlwell MP, Wolmark N
|
|
123.
|
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. MedStar authors:
Year: 2020
Citation: - Clinical Cancer Research. 26(6):1258-1266, 2020 03 15.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Attia S, Bolejack V, Burgess M, Davis LE, Hu J, Keung EZ, Lazar AJ, Movva S, Okuno S, Parra Cuentas E, Priebat DA, Reed DR, Reinke DK, Reuben A, Riedel RF, Rodrigues-Canales J, Roland CL, Salazar R, Schuetze SM, Tawbi HA, Van Tine BA, Wang WL, Wargo JA
|
|
124.
|
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. MedStar authors:
Year: 2013
Citation: - Annals of Oncology. 24(10):2630-5, 2013 Oct.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Clark E, Cortes J, Im SA, Im YH, Knott A, Pivot X, Ross G, Swain SM
|
|
125.
|
Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. MedStar authors:
- Burman, Kenneth D
- Klubo-Gwiezdzinska, Joanna
- Wartofsky, Leonard
Citation: - Endocrine-Related Cancer. 19(3):447-56, 2012 Jun.
Institution: - MedStar Washington Hospital Center
Medline publication type:
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Bauer A, Burman KD, Costello J, Hoperia V, Jensen K, Klubo-Gwiezdzinska J, Patel A, Vasko V, Wartofsky L
|
|
126.
|
|
|
127.
|
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. MedStar authors:
Year: 2013
Citation: - Lancet Oncology. 14(6):461-71, 2013 May.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, Cortes J, Ferrero JM, Kim SB, Knott A, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM
|
|
128.
|
|
|
129.
|
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung. MedStar authors:
Year: 2021
Citation: - Journal for Immunotherapy of Cancer. 9(2), 2021 02.
Institution:
- MedStar Washington Hospital Center
- Washington Cancer Institute
Department: - Medicine/Internal Medicine
Medline publication type:
All authors: - Bar J, Dudnik E, Gottfried T, Israel Lung Cancer Group, Kareff S, Kim C, Liu SV, Lobachov A, Moskovitz M, Onn A, Rotem O, Urban D, Wollner M, Zer A
|
|
130.
|
NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response. MedStar authors:
Year: 2020
Citation: - Clinical Cancer Research. 26(16):4233-4241, 2020 08 15.
Department: - Associate Dean for Research Development
Medline publication type:
All authors: - Bandos H, Brauer HA, Geyer CE Jr, Goerlitz DS, Harris BT, Lucas PC, Mamounas EP, Rastogi P, Ren Y, Robidoux A, Swain SM, Tang G, Wolmark N
|
|
131.
|
Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer. MedStar authors:
Year: 2019
Citation: - Journal of Investigative Medicine High Impact Case Reports. 7:2324709619890942, 2019 Jan-Dec.
Institution: - MedStar Washington Hospital Center
Medline publication type:
All authors: - Burman KD, Fazeli S, Khosla SG, Maxwell JH, Nylen ES, Paal E
|
|
132.
|
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. MedStar authors:
Year: 2017
Citation:
- JAMA Oncology. , 2017 Feb 09
- JAMA Oncology. 3(7):944-952, 2017 Jul 01
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Baker LH, Benjamin RS, Blackstein ME, Blanke CD, Borden EC, Corless CL, Crowley JJ, Demetri GD, Fletcher JA, Heinrich M, Maki RG, Owzar K, Priebat DA, Rankin C, Ryan CW, Tap WD, von Mehren M
|
|
133.
|
Bevacizumab added to neoadjuvant chemotherapy for breast cancer. MedStar authors:
Year: 2012
Citation: - New England Journal of Medicine. 366(4):310-20, 2012 Jan 26.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, P.H.S.
All authors: - Adams PT, Atkins JN, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Mamounas EP, Margolese RG, Mehta RS, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA
|
|
134.
|
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. MedStar authors:
Year: 2022
Citation: - Journal of Clinical Oncology. 40(5):438-448, 2022 02 10.
Department: - Associate Dean for Research Development
Medline publication type:
All authors: - Barrios C, Bonnefoi H, Boulet T, De Laurentiis M, Ellis PA, Fehrenbacher L, Gianni L, Gralow J, Harbeck N, Huang CS, Im SA, Im YH, Ito Y, Krop IE, Liu H, Macharia H, Nowecki Z, Shah J, Song C, Swain SM, Toi M, Trask P, Winer EP
|
|
135.
|
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. MedStar authors:
Year: 2013
Citation: - Anti-Cancer Drugs. 24(10):1084-92, 2013 Nov.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Brewster M, Cortes J, Garg A, Grincuka E, Hauschild M, Kudaba I, Lum BL, Marier JF, Masuda N, McNally V, Nijem I, Patel T, Ross G, Swain SM, Trinh MM, Visich J
|
|
136.
|
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2. MedStar authors:
- Swain, Sandra M
- Zapas, John L
Year: 2017
Citation: - Journal of Clinical Oncology. 35(35):3942-3948, 2017 Dec 10
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Atkins JN, Biggs DD, Brufsky AM, Cecchini RS, Fehrenbacher L, Flynn PJ, Ganz PA, Geyer CE Jr, Gross HM, Jeong JH, Mamounas EP, Polikoff J, Rastogi P, Romond EH, Seay TE, Swain SM, Wade JL 3rd, Wahl TA, Wolmark N, Zapas JL
|
|
137.
|
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. MedStar authors:
- Asch, Federico M
- Barac, Ana
- Cunningham, A
- Gallagher, Christopher
- Hofmeyer, Mark
- Srichai, M B
- Swain, Sandra M
Year: 2019
Citation: - Breast Cancer Research & Treatment. 175(3):595-603, 2019 Jun.
Institution:
- MedStar Health
- MedStar Health Research Institute
- MedStar Heart & Vascular Institute
- Washington Cancer Institute
Department: - Associate Dean for Research Development
Medline publication type:
All authors: - Asch FM, Barac A, Cunningham A, Dang C, Gallagher C, Geng X, Herbolsheimer P, Hofmeyer M, Isaacs C, Lynce F, Nunes R, Pohlmann PR, Shajahan-Haq A, Smith KL, Srichai MB, Swain SM, Tan MT, Timothee P, Warren R, Yu AF
|
|
138.
|
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. MedStar authors:
Year: 2017
Citation: - Clinical Breast Cancer. 17(1):48-54.e3, 2017 Feb
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Ansari B, Buyse ME, Conlin AK, Geyer CE Jr, Gross HM, Jacobs SA, Keogh GP, Lord RS, Mamounas EP, Mauquoi C, Patocskai EJ, Polikoff JA, Rastogi P, Robidoux A, Smith JW 2nd, Stella PJ, Swain SM, Wolmark N
|
|
139.
|
|
|
140.
|
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. MedStar authors:
Year: 2017
Citation: - Lancet Oncology. 18(12):1600-1609, 2017 Dec
Institution: - MedStar Franklin Square Hospital
Medline publication type:
All authors: - Brahmer JR, Csoszi T, Cuffe S, Deitz AC, Fulop A, Gottfried M, Hotta K, Hui R, Lubiniecki GM, O'Brien M, Peled N, Rangwala R, Rao S, Reck M, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Zhang J
|
|
141.
|
Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma. MedStar authors:
Year: 2016
Citation: - Cancer. 122(1):124-30, 2016 Jan 1.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
All authors: - Atkins MB, Barac A, Freedman AN, Fu AZ, Jang S, Minasian L, Potosky AL, Tsai HT, Zheng C
|
|
142.
|
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. MedStar authors:
Year: 2013
Citation: - Lancet Oncology. 14(12):1183-92, 2013 Nov.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Comparative Study
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Atkins JN, Azar CA, Baez-Diaz L, Bandos H, Bear HD, Brufsky AM, Costantino JP, Farrar WB, Fehrenbacher L, Geyer CE Jr, Mamounas EP, Margolese RG, Paik S, Rastogi P, Robidoux A, Sarwar S, Shibata HR, Swain SM, Tang G, Wolmark N
|
|
143.
|
SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. MedStar authors:
- Asch, Federico M
- Barac, Ana
- Lynce, Filipa
- Swain, Sandra M
Year: 2017
Citation: - Oncologist. 22(5):518-525, 2017 May
Institution:
- MedStar Heart & Vascular Institute
- Washington Cancer Institute
Medline publication type:
All authors: - Asch FM, Barac A, Dang C, Isaacs C, Lynce F, Smith KL, Swain SM, Tan MT
|
|
144.
|
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. MedStar authors:
Year: 2019
Citation: - Journal of Clinical Oncology. 37(7):537-546, 2019 03 01.
Institution: - Medstar Franklin Square Medical Center
Medline publication type:
All authors: - Brahmer JR, Csoszi T, Cuffe S, Fulop A, Gottfried M, Hotta K, Hui R, O'Brien M, Peled N, Pietanza MC, Rao S, Reck M, Riccio A, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Vandormael K, Yang J
|
|
145.
|
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. MedStar authors:
Year: 2012
Citation: - Journal of Clinical Oncology. 30(12):1268-73, 2012 Apr 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Comparative Study
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Allred DC, Anderson SJ, Costantino JP, Geyer CE Jr, Julian TB, Land SR, Mamounas EP, Nagtegaal ID, Paik S, Swain SM, Wickerham DL, Wolmark N
|